The Power and the Promise of Liver Cancer Stem Cell Markers

Liu, Li-Li; Fu, Da; Ma, Yu‐Shui; Shen, Xizhong

doi:10.1089/scd.2011.0012

Cited by 85 publications

(71 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Combining more than one marker has been shown to increase the isolating efficiency [21,22]. However, in immunohistochemistry analysis, we could not reveal a ubiquitous co-expression pattern between any of the LCSC markers.…”

Section: Discussioncontrasting

confidence: 77%

“…The expression of CD44 in HCC is also related to a higher frequency of extrahepatic metastasis and poor survival [37]. It has, thus, been suggested that the combination of CD44 with other markers such as CD90 + / CD44 + and CD44 + /CD133 + may be of more value in isolating LCSCs [21,22]. Our data shows high expression of CD44 in most HCC (8/14), and CD44 appears to co-express with many of the other CSC markers studied.…”

Section: Discussionmentioning

confidence: 99%

“…Several LCSC markers have been reported, including CD133, CD90, CD44, epithelial cell-adhesion molecule (EpCAM), CD13, OV6, and ALDH [19,20]. However, the reliability of each of these markers in identifying true LCSCs varies with LCSCs sorted from different laboratories showing high heterogeneity [21]. LCSCs isolated using different markers may show similar stemness.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Efficacy of Using Cancer Stem Cell Markers in Isolating and Characterizing Liver Cancer Stem Cells

Wilson

Duan

et al. 2013

Stem Cells and Development

View full text Add to dashboard Cite

Recent evidence suggests that a subset of hepatocellular carcinomas (HCCs) are derived from liver cancer stem cells (LCSCs). In order to isolate and characterize LCSCs, reliable markers that are specific to these cells are required. We evaluated the efficacy of a range of cancer stem cell (CSC) markers in isolating and characterizing LCSCs. We show that the most widely used CSC markers are not specific to LCSCs. By western analysis, protein expression of the common markers showed no significant difference between HCC tumor tissues and adjacent non-cancerous liver. Further, isolation of LCSCs from common HCC cell lines using FACScan and microbeads showed no consistent marker expression pattern. We also show that LCSCs have unique subtypes. Immunohistochemistry of HCC tissues showed that different HCCs express unique combinations of LCSC markers. Quantitative real-time polymerase chain reaction analysis showed that LCSCs isolated using different markers in the same HCC phenotype had different expression profiles. Likewise, LCSCs isolated from different HCC phenotypes with the same marker also had unique expression profiles and displayed varying resistance profiles to Sorafenib. Thus, using a range of commonly used CSC markers in HCCs and cell lines, we demonstrate that currently available markers are not specific for LCSCs. LCSCs have unique subtypes that express distinctive combinations of LCSC markers and altered drug resistance profiles, making their identification problematic.

show abstract

Section: Discussioncontrasting

confidence: 77%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of Using Cancer Stem Cell Markers in Isolating and Characterizing Liver Cancer Stem Cells

Wilson

Duan

et al. 2013

Stem Cells and Development

View full text Add to dashboard Cite

show abstract

“…If physiological stem cell features like SP and ALDH or cell surface markers are measured exclusively, they have their limitations to identify CSCs unequivocally, especially when tumor tissue is analyzed (137). For example, SP analysis alone was not sufficient to define a CSC phenotype in glioblastoma multiforme (138) and this was also the case for CD44 1 /CD24 -cells in breast cancer (139).…”

Section: Combination Of Sp Aldh1 and Cell Surface Markersmentioning

confidence: 99%

Flow cytometry in cancer stem cell analysis and separation

et al. 2012

View full text Add to dashboard Cite

In recent years, a special type of cancer cell-the cancer stem cell (CSC)-has been identified and characterized for different tumors. CSCs may be responsible for the recurrence of a tumor following a primarily successful therapy and are thought to bear a high metastatic potential. For the development of efficient treatment strategies, the establishment of reliable methods for the identification and effective isolation of CSCs is imperative. Similar to their stem cell counterparts in bone marrow or small intestine, different cluster of differentiation surface antigens have been characterized, thus enabling researchers to identify them within the tumor bulk and to determine their degree of differentiation. In addition, functional properties characteristic of stem cells can be measured. Side population analysis is based on the stem cell-specific activity of certain ATP-binding cassette transporter proteins, which are able to transport fluorescent dyes out of the cells. Furthermore, the stem cell-specific presence of aldehyde dehydrogenase isoform 1 can be used for CSC labeling. However, the flow cytometric analysis of these CSC functional features requires specific technical adjustments. This review focuses on the principles and strategies of the flow cytometric analysis of CSCs and provides an overview of current protocols as well as technical requirements and pitfalls. A special focus is set on side population analysis and analysis of ALDH activity. Flow cytometrybased sorting principles and future flow cytometric applications for CSC analysis are also discussed. ' 2012 International Society for Advancement of Cytometry

show abstract

“…CD13, also known as aminopeptidase N, is a membranous glycoprotein that plays important roles in cancer progression including cell proliferation, invasion, and angiogenesis [70][71][72]. Christ et al [73] demonstrated that CD13(+) cells predominated in the G0 phase of the cell cycle and typically formed cellular clusters in cancer foci.…”

Section: Cd13mentioning

confidence: 99%

Surface markers of hepatocellular cancer stem cells and their clinical potential

Feng¹,

Wang²,

Hu³

et al. 2014

neo

View full text Add to dashboard Cite

Cancer stem cells (CSCs) are a small subpopulation of cells within tumors with capabilities of self-renewal, differentiation, and tumorigenicity when transplanted into immune-comprised mice. Accumulating evidences have shown that CSCs or tumor-initiating cells are key drivers of tumor formation and progression in both solid tumors and haematological malignancies. Identification of the CSCs or tumor-initiating cells is a fundamental and important problem in cancer research. There is still a lack of consensus regarding the existence of a "global" marker for CSCs in different human cancers, but isolated CSCs have shown both the tumor-propagating ability in immune-compromised mice and the capacity to fully recapitulate the original heterogeneity of cell types. Several cell surface markers, including CD133, CD44 and CD90, were often used to identify and enrich CSCs. Although not all types of cancer follow the CSC theory, it provides an attractive cellular mechanism to account for the therapeutic resistance and recurrence of the disease. Here we provide a brief review regarding the markers for identification of CSCs in hepatocellular cancer, allowing us to deep understand of the cellular organization of HCC and to develop therapies that target specific CSCs.

show abstract

The Power and the Promise of Liver Cancer Stem Cell Markers

Cited by 85 publications

References 77 publications

Efficacy of Using Cancer Stem Cell Markers in Isolating and Characterizing Liver Cancer Stem Cells

Efficacy of Using Cancer Stem Cell Markers in Isolating and Characterizing Liver Cancer Stem Cells

Flow cytometry in cancer stem cell analysis and separation

Surface markers of hepatocellular cancer stem cells and their clinical potential

Contact Info

Product

Resources

About